MECP2 and pancreatic adenocarcinoma: Here, HDAC2 protein levels did not alter upon MECP2 overexpression, suggesting that HDAC2 did not facilitate the observed increase in the expression of Il6 and Tnf. In pancreatic adenocarcinoma cell lines, Dandrea et al. found a possible MECP2 binding site in the IL6 upstream region and chromatin immunoprecipitation experiments in synovial fibroblasts have shown binding of MECP2 to the IL6 promoter [60,61].